FDA DEVICE FACTS
Fassier-Duval Telescopic IM System
Pega Medical, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
This implant is indicated as a temporary implant to aid in the healing of long diaphysis fractures, osteotomies, malunions and nonunions and to prevent further fractures in femur, tibia and humerus in pediatric patients suffering from Osteogenesis Imperfecta without disrupting the bone growth plate. It can be used in procedures such as bone lengthening/shortening concomitantly with external fixators in pediatric or small stature patients with limb length discrepancy. Description: The Fassier-Duval Telescopic IM System is a telescopic rod for use in fixation of long bone fractures. The design of the nail includes a female component (which is attached to the proximal -trochanteric- cortex of the bone) and a male component (which is attached to the distal cortex of the bone). Anchorage of the components is achieved through screw-type fixation. The nail is composed of two sliding components that allow for extension of its length as the bone structures heal and normal patient growth occurs. The Pega Med ical Fassier-Duval Telescopic IM System can be attached to bony structures without disrupting the bone growth plates. This Special 510(k) Premarket Notification is submitted for the additional offering of gamma sterilized Ø3.2
– Ø6.4 stainless steel Fassier-Duval implant components. All subject components have previously been cleared as non-sterile implants. All other components of the Fassier-Duval Telescopic IM System will remain non-sterile to be sterilized by end-user. Basis for substantial equivalence: The technological characteristics (materials, design, sizing) of the Fassier-Duval Telescopic IM System are identical to the predicate Pega Medical Fassier-Duval Telescopic IM System (K020885 & K041393). The rationale for substantial equivalence is based on consideration of the following characteristics:
• Intended Use: The intended use is identical to the predicate ( K020885 & K041393).
• Indications for Use: Indications for Use are identical to the predicate ( K020885 & K041393).
• Materials: Materials are identical to the predicate (K020885 & K041393).
• Design Features: Design features are identical to the predicate (K020885 & K041393).
• Function: The function is identical to the predicate (K020885 & K041393).
• Sterilization: The proposed Fassier-Duval Telescopic IM System seeks to add sterile packaged nails for distribution. All subject components have previously been cleared as non-sterile implants. All other components will remain non-sterile to be sterilized by end-user. Non-clinical Performance Data: No significant design changes have been made since the previous submission. Gamma sterilization validation, sterile packaging validation, integrity of the sterile barrier over time validation, and rinsing validation were performed to qualify the new packaging and sterilization method for the Fassier -Duval Telescopic IM system. Ba cterial Endotoxin Testing was conducted in accordance with ANSI/AAMI ST72:2019. Clinical Performance Data: No clinical testing is provided as a basis for substantial equivalence.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。